Clinical trials: Docetaxel, completed
Prostate Cancer
CTC Immune Checkpoint
This pilot study will explore the prevalence of expression of four immune checkpoint biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that are captured by EpCAM via the CellSearch method, and…
- Trial name
- NCT02456571
- Testing
- CTC biomarker expression prevalence
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Duke University
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
This phase I trial investigates how well pembrolizumab and chemoradiotherapy works in treating patients with gastroesophageal cancer that cannot be removed by surgery (unresectable).
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04522336
- Testing
- Docetaxel, Fluorouracil, Oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate, Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer.
- Trial name
- NCT00165399
- Testing
- Docetaxel, Estramustine, Casodex
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial
The purpose of the trial is to determine the feasibility of an induction chemotherapy with radio-immunotherapy in patients with head and neck cancer stage III/IV
- Trial name
- ASOG-HNO1 (NCT00502463)
- Testing
- Docetaxel, Cisplatin, 5-FU
- Where
- 5 sites in Austria
- Volunteers
- 51 people
- Sponsor
- Austrian South Oncology Group
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Triple-Negative Breast Cancer
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy and targeted therapy are completely ineffective, chemotherapy is currently the only effective treatment.
- Trial name
- LANCET (NCT03243838)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Guangdong Provincial People's Hospital
Gastric Adenocarcinoma
S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma
Currently, for further improved survival outcome, new cytotoxic compounds such as irinotecan and docetaxel have been combined with 5-FU/cisplatin.
- Trial name
- NCT02495493
- Testing
- Induction DCS chemotherapy
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Yonsei University
Advanced Solid Tumours
Extended Use of ModraDoc006/r
This is a study for extended use of ModraDoc006/r in patients with advanced solid tumours, available after completed treatment in one of the phase I trials with ModraDoc006/r.
- Trial name
- NCT03150368
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Modra Pharmaceuticals
Lung Cancer
Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005868
- Testing
- cisplatin, docetaxel
- Where
- 23 sites in Germany, Italy and 3 more
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
- Trial name
- NCT00466440
- Testing
- enzastaurin, docetaxel, prednisone
- Where
- 28 sites in United States, Germany and 1 more
- Volunteers
- 108 people
- Sponsor
- Eli Lilly and Company
Non-squamous NSCLC, HER2 Exon 20 Mutation
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a…
- Trial name
- PYRAMID-1 (NCT04447118)
- Testing
- Pyrotinib, Docetaxel
- Where
- 102 sites in United States, Australia and 11 more
- Volunteers
- 151 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290693
- Testing
- Capecitabine, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Prostate Cancer
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
- Trial name
- CheckMate 7DX (NCT04100018)
- Testing
- Nivolumab, Prednisone, Docetaxel
- Where
- 293 sites in United States, Argentina and 26 more
- Volunteers
- 1,030 people
- Sponsor
- Bristol-Myers Squibb
Chemo-brain, Drug-Related Side Effects and Adverse Reactions
Acupuncture Prevents Chemobrain in Breast Cancer Patients
Chemobrain is an expression used to describe a cluster of chemotherapy-induced cognitive impairment symptoms, including problems with visual and verbal memory, forgetfulness, difficulty in learning, attention, concentration and…
- Conditions
- Chemo-brain, Drug-Related Side Effects and Adverse Reactions, Mild Cognitive Impairment, Breast Cancer
- Trial name
- NCT02457039
- Testing
- Dense cranial electroacupuncture stimulation, Body acupuncture, Least acupuncture stimulation
- Where
- 6 sites in China, Hong Kong
- Volunteers
- 93 people
- Sponsor
- The University of Hong Kong
Immune-related Adverse Event, Chemotherapeutic Toxicity
Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
The goal of the study is to learn about Safety and efficacy of preoperative adjuvant SOX regimen combined with nivolumab versus FLOT Regimen with nivolumab in HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06440811
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Solid Tumor
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
The purpose of this study is to find the highest dose of the combination of taxotere, cisplatin and CPT-11, that can be given without causing severe side effects.
- Trial name
- NCT00251407
- Testing
- Taxotere, Cisplatin, CPT-11
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy
The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.
- Trial name
- SPAM (NCT00911911)
- Testing
- Blood sampling, BIOPSY, SURGERY
- Where
- 5 sites in France
- Volunteers
- 66 people
- Sponsor
- Centre Oscar Lambret
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hormone Refractory Prostate Cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of…
- Trial name
- NCT00571675
- Testing
- AT-101, prednisone and docetaxel
- Where
- 35 sites in United States, Russia
- Volunteers
- 220 people
- Sponsor
- Ascenta Therapeutics
Breast Cancer
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
This is an open-label, single-arm, multicenter, Phase IIIb study to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in female patients with HER2-positive metastatic or locally…
- Trial name
- NCT02402712
- Testing
- Docetaxel, pertuzumab [Perjeta], trastuzumab [Herceptin]
- Where
- 112 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 418 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.